| Last Call for Med-e-Tel 2010 Early Bird Registration 14-16 April 2010, Luxembourg. The Med-e-Tel forum is the ideal opportunity to follow up on the latest developments and initiatives in Telemedicine and eHealth and to exchange ideas and experiences related to ICT applications in healthcare. Register on or before Monday, 15th March, 2010 and get the early bird rate for your Med-e-Tel registration. |
| Final Line-Up for the Inaugural Health 2.0 Conference in Europe 6-7 April 2010, Paris, France. Health 2.0 Europe will take place at the Cité Internationale Universitaire in Paris. This event will feature the three integral components of Health 2.0 in a rapid-fire live demo format where leading examples of Health 2.0 in North America will be compared and contextualized with the latest in European innovation. |
| Pfizer Discontinues A Phase 3 Study Of Figitumumab Pfizer Inc. announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC). |
| Sanofi-aventis Successfully Completes the Acquisition of Chattem, Inc. Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has completed its acquisition of 100% of Chattem, Inc., which is now a wholly-owned subsidiary of the sanofi-aventis Group. |
| Electronic Clinical Decision Support for Middle Eastern Hospitals Hospitals in the Middle East are set to benefit from sophisticated electronic clinical decision support following the commercial agreement between First DataBank International (FDB International) and GE Healthcare (GE). |
| Roche and Biogen Idec decide to suspend Ocrelizumab treatment Roche and Biogen Idec announced their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA) programme. The decision follows the recommendation of the independent Ocrelizumab RA & Lupus Data and Safety Monitoring Board (DSMB) based on their assessment of the studies in RA (SCRIPT, FEATURE, FILM and STAGE) and lupus (BELONG and BEGIN). |
| Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech Abbott (NYSE: ABT) and Facet Biotech Corporation (Nasdaq: FACT) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline. |
| Novel Drug for Chronic Management of Hyperuricemia in Gout Patients Teijin Pharma Limited announced the European launch of TMX-67 (febuxostat), a novel drug discovered by Teijin Pharma for the treatment of hyperuricemia in patients with gout. Ipsen, a global biotechnology specialty care group and the TMX-67 licensee in Europe, and its sublicensee the Menarini Group, the first Italian pharmaceutical group in the world, have began marketing the product in Europe under the brand name ADENURIC(r). |
| Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZAâ?¢ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors. |
| Google Announces Public Data Explorer Google announces an addition to Google Labs - the Public Data Explorer. The purpose of the new tool, Google says on the new lab's page, "The Google Public Data Explorer makes large datasets easy to explore, visualize and communicate. |
The content of these articles do not reflect the opinion of Triple i, MediMedia USA, or their employees.